RxDoctor Payments Data

Dadong Zhou, MD

Neurology · Edmonds, WANPI 1619997582

Payments from drug & device makers

$3,158in general payments, 2019–2025

Across 61 payments — averaging $51.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$2K
  • AbbVie$672
  • Teva Pharmaceuticals USA, Inc.$298
  • Novartis$211
  • Medtronic$130
  • Nevro Corp.$103
  • plus $244 from 6 others
$490in research payments, 2019–2025

Across 1 payment — averaging $490.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$490

What the payments were for

  • Consulting fees$1,63052%
  • Speaking & faculty fees$34511%
  • Food & beverage$1,18337%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,158 in reported general payments places this provider in the 75th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$121,334
Medicare patients
448
Services billed
5,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant42$51,674
Nurtec OdtRimegepant Sulfate30$46,265
Aimovig AutoinjectorErenumab-Aooe36$28,487
Emgality PenGalcanezumab-Gnlm15$18,950
Levetiracetam318$9,066
Carbamazepine ErCarbamazepine57$8,891
Carbidopa-LevodopaCarbidopa/Levodopa292$7,831
Lacosamide45$5,244
Primidone262$4,272
Tegretol XrCarbamazepine13$3,730
Mycophenolate Mofetil22$3,703
Gabapentin132$2,681
Nortriptyline Hcl59$2,637
Lamotrigine101$2,551
Pramipexole DihydrochloridePramipexole Di-Hcl71$2,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$672$51,67442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 418 neurology providers in Washington.

Other neurology in Edmonds

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →